During the study, 50 migraine patients randomly received either topically applied timolol maleate ophthalmic solution, 0.5%, or placebo eyedrops.
Cassandra Pardini, PharmD
Contributing Writer
Cassandra Pardini is a freelance writer and registered pharmacist with a diverse background in drug therapy, scientific research, and the drug discovery and developmental process. She obtained her Doctor of Pharmacy degree from the Massachusetts College of Pharmacy and Health Sciences University, Master of Science degree in chemistry and chemical biology from Northeastern University, and Bachelor of Science degree in chemistry from Boston College. She currently lives in Rhode Island with her husband and 3 children.
